Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • Kate Attfield, University of Oxford, Oxford
  • ,
  • Astrid Kn Iversen, University of Oxford, Oxford
  • ,
  • Ralf Gold, Ruhr Univ Bochum, Ruhr University Bochum, MHRTC
  • ,
  • Lars Fugger
  • Aiden Haghikia, Ruhr Univ Bochum, Ruhr University Bochum, MHRTC

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.

TidsskriftMultiple sclerosis (Houndmills, Basingstoke, England)
Sider (fra-til)1261-1264
Antal sider4
StatusUdgivet - sep. 2020
Eksternt udgivetJa

Se relationer på Aarhus Universitet Citationsformater

ID: 198445124